| Fiscal Period | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Period End Date | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
| Total Liabilities Shareholders' Equity | 4,273.78 | 3,994.13 | 3,553.87 | 2,607.40 |
| Accumulated Depreciation Total | -770.31 | -700.38 | -643.49 | -582.92 |
| Cash Equivalents | 36.00 | 23.50 | 26.91 | 1.82 |
| Other Liabilities Total | 24.43 | 20.09 | 17.70 | 16.90 |
| Long Term Debt | 0.00 | 23.64 | 383.22 | - |
| Common Stock Total | 15.57 | 15.52 | 15.48 | 15.46 |
| Other Equity Total | -1.90 | -14.87 | -3.97 | 9.38 |
| Other Current Assets Total | 4.35 | 3.40 | 3.21 | 8.28 |
| Prepaid Expenses | 19.01 | 16.32 | 16.70 | 12.04 |
| Total Assets | 4,273.78 | 3,994.13 | 3,553.87 | 2,607.40 |
| Current Portof LT Debt/ Capital Leases | 7.73 | 329.04 | 145.89 | 33.94 |
| Additional Paid- In Capital | 164.06 | 113.39 | 69.73 | 50.77 |
| Cash | 79.09 | 64.71 | 50.02 | 54.72 |
| Total Equity | 3,433.32 | 2,923.33 | 2,480.35 | 2,134.12 |
| Long Term Investments | 278.39 | 28.51 | 27.40 | 17.54 |
| Retained Earnings( Accumulated Deficit) | 3,255.24 | 2,808.94 | 2,398.76 | 2,058.17 |
| Total Common Shares Outstanding | 15.57 | 15.52 | 15.48 | 15.46 |
| Property/ Plant/ Equipment Total- Gross | 1,426.96 | 1,335.26 | 1,219.91 | 1,149.74 |
| Tangible Book Valueper Share Common Eq | 132.24 | 95.20 | 71.12 | 90.92 |
| Goodwill Net | 57.46 | 57.46 | 57.46 | 57.46 |
| Total Liabilities | 840.46 | 1,070.80 | 1,073.52 | 473.28 |
| Total Debt | 27.89 | 377.66 | 572.45 | 54.56 |
| Short Term Investments | 335.00 | 371.42 | 192.27 | 1.21 |
| Cashand Short Term Investments | 450.09 | 459.64 | 269.20 | 57.75 |
| Total Receivables Net | 901.55 | 860.19 | 794.84 | 755.73 |
| Notes Payable/ Short Term Debt | 13.80 | 15.34 | 28.02 | 0.00 |
| Deferred Income Tax | 177.34 | 149.21 | 102.82 | 47.56 |
| Accounts Receivable- Trade Net | 816.44 | 687.43 | 576.19 | 555.69 |
| Property/ Plant/ Equipment Total- Net | 656.64 | 634.88 | 576.42 | 566.82 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 4.49 |
| Total Current Liabilities | 632.34 | 868.23 | 554.45 | 383.72 |
| Total Inventory | 547.73 | 513.79 | 444.08 | 441.05 |
| Accounts Payable | 410.72 | 356.31 | 238.65 | 224.48 |
| Other Currentliabilities Total | 200.09 | 167.54 | 141.87 | 125.29 |
| Total Long Term Debt | 6.35 | 33.28 | 398.54 | 20.62 |
| Intangibles Net | 1,317.14 | 1,388.45 | 1,322.28 | 671.39 |
| Other Long Term Assets Total | 14.39 | 12.28 | 12.38 | 7.38 |
| Note Receivable- Long Term | 27.01 | 19.20 | 29.89 | 11.95 |
| Unrealized Gain( Loss) | 0.35 | 0.35 | 0.35 | 0.35 |
| period Length | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 1,922.74 | 1,853.35 | 1,528.03 | 1,274.86 |
| Capital Lease Obligations | 6.35 | 9.64 | 15.32 | 20.62 |
| Accrued Expenses | - | 0.00 | 0.03 | 0.01 |
J B Chemicals and Pharmaceuticals Dividend J B Chemicals and Pharmaceuticals Bonus J B Chemicals and Pharmaceuticals News J B Chemicals and Pharmaceuticals AGM J B Chemicals and Pharmaceuticals Rights J B Chemicals and Pharmaceuticals Splits J B Chemicals and Pharmaceuticals Board Meetings J B Chemicals and Pharmaceuticals Key Metrics J B Chemicals and Pharmaceuticals Shareholdings J B Chemicals and Pharmaceuticals Profit Loss J B Chemicals and Pharmaceuticals Cashflow J B Chemicals and Pharmaceuticals Q1 Results J B Chemicals and Pharmaceuticals Q2 Results J B Chemicals and Pharmaceuticals Q3 Results J B Chemicals and Pharmaceuticals Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks